Teva Pharmaceutical (Germany) Performance
| TEV Stock | EUR 21.20 0.70 3.41% |
On a scale of 0 to 100, Teva Pharmaceutical holds a performance score of 11. The entity has a beta of -0.72, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Teva Pharmaceutical are expected to decrease at a much lower rate. During the bear market, Teva Pharmaceutical is likely to outperform the market. Please check Teva Pharmaceutical's expected short fall, daily balance of power, and the relationship between the downside variance and kurtosis , to make a quick decision on whether Teva Pharmaceutical's existing price patterns will revert.
Risk-Adjusted Performance
11 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Teva Pharmaceutical Industries are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Teva Pharmaceutical reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 2.2 B |
Teva |
Teva Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 1,565 in Teva Pharmaceutical Industries on September 22, 2024 and sell it today you would earn a total of 555.00 from holding Teva Pharmaceutical Industries or generate 35.46% return on investment over 90 days. Teva Pharmaceutical Industries is currently producing 0.5198% returns and takes up 3.6428% volatility of returns over 90 trading days. Put another way, 32% of traded stocks are less volatile than Teva, and 90% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Teva Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Teva Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Teva Pharmaceutical Industries, and traders can use it to determine the average amount a Teva Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1427
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TEV | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.64 actual daily | 32 68% of assets are more volatile |
Expected Return
| 0.52 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 11 89% of assets perform better |
Based on monthly moving average Teva Pharmaceutical is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Teva Pharmaceutical by adding it to a well-diversified portfolio.
Teva Pharmaceutical Fundamentals Growth
Teva Stock prices reflect investors' perceptions of the future prospects and financial health of Teva Pharmaceutical, and Teva Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Teva Stock performance.
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 | |||
| Profit Margin | (0.16) % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 28.17 B | |||
| Shares Outstanding | 1.11 B | |||
| Price To Book | 1.16 X | |||
| Price To Sales | 0.61 X | |||
| Revenue | 14.93 B | |||
| EBITDA | (827 M) | |||
| Cash And Equivalents | 1.97 B | |||
| Cash Per Share | 1.81 X | |||
| Total Debt | 19.1 B | |||
| Debt To Equity | 184.30 % | |||
| Book Value Per Share | 7.11 X | |||
| Cash Flow From Operations | 1.59 B | |||
| Earnings Per Share | (1.96) X | |||
| Total Asset | 44.01 B | |||
About Teva Pharmaceutical Performance
By analyzing Teva Pharmaceutical's fundamental ratios, stakeholders can gain valuable insights into Teva Pharmaceutical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Teva Pharmaceutical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Teva Pharmaceutical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel. TEVA PHARMACEUT operates under Drug Manufacturers - Specialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 42535 people.Things to note about Teva Pharmaceutical performance evaluation
Checking the ongoing alerts about Teva Pharmaceutical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Teva Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Teva Pharmaceutical appears to be risky and price may revert if volatility continues | |
| Teva Pharmaceutical has high likelihood to experience some financial distress in the next 2 years | |
| Teva Pharmaceutical has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Teva Pharmaceutical Industries has accumulated 19.1 B in total debt with debt to equity ratio (D/E) of 184.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Teva Pharmaceutical has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Teva Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Teva Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Teva Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Teva to invest in growth at high rates of return. When we think about Teva Pharmaceutical's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 14.93 B. Net Loss for the year was (2.35 B) with profit before overhead, payroll, taxes, and interest of 6.97 B. |
- Analyzing Teva Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Teva Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Teva Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Teva Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Teva Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Teva Pharmaceutical's stock. These opinions can provide insight into Teva Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Teva Stock analysis
When running Teva Pharmaceutical's price analysis, check to measure Teva Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharmaceutical is operating at the current time. Most of Teva Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Teva Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharmaceutical's price. Additionally, you may evaluate how the addition of Teva Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |